James Maitland has spent his career at the intersection of medical technology and health systems, observing how data-driven innovations can either revolutionize patient care or complicate the financial landscape of public health. As an expert in robotics and IoT applications, he brings a unique perspective to the mechanical and digital processes that drive insurance reimbursement. His deep understanding of how information is captured at the point of care allows him to dissect the complexities of Medicare Advantage, a program that now covers more than half of all eligible seniors. Today, he joins us to discuss the regulatory shifts and technical challenges involved in curbing the estimated $76 billion in annual overpayments that currently strain the federal budget.
Federal spending on Medicare Advantage currently exceeds traditional Medicare costs by an estimated $76 billion annually. How does the flat-fee payment structure incentivize aggressive coding practices, and what specific metrics should regulators prioritize to identify where diagnosis inflation is occurring?
The core of the issue lies in the transition from fee-for-service to a capitated, flat-fee model where private insurers receive a monthly payment per member. When the government adjusts these payments based on how “sick” a member is, it creates a powerful financial motive for payers to document every possible ailment, sometimes inflating minor issues into significant chronic conditions to maximize that $76 billion pool. To counter this, regulators must look closely at coding intensity metrics, specifically comparing the volume of high-risk diagnoses in privatized plans against the baseline of traditional Medicare. We should prioritize tracking the “diagnosis-to-encounter” ratio, which highlights instances where a serious illness is reported on paper but doesn’t result in a corresponding medical procedure, prescription, or follow-up visit. It is this gap between the reported sickness and the actual medical intervention that signals where inflation is likely occurring.
Policy shifts may soon exclude diagnoses from chart reviews and health risk assessments not tied to specific medical encounters. How do insurers currently use these reviews to capture health risks, and what are the practical implications for patient care if these data points are removed from reimbursement calculations?
Currently, insurers employ massive teams or automated systems to perform retrospective chart reviews, scouring old records to find missed codes that can be submitted for additional payment without the patient ever seeing a doctor for that specific issue. Health risk assessments often function similarly, acting as screenings that trigger higher reimbursement tags but don’t necessarily lead to a new treatment plan. If we remove these “unlinked” data points, the practical implication is a return to patient-centered care where a diagnosis only “counts” if it is actually being managed by a clinician. While some argue this might lead to under-reporting, it forces the system to focus on active medical encounters, ensuring that federal funds are tied to the physical reality of a patient sitting in an exam room rather than a line item found in a database.
There is a push to utilize two years of diagnostic data rather than one to better track chronic conditions. How would this change provide a clearer picture of member health, and what step-by-step technical adjustments would health plans need to make to their reporting systems?
Moving to a two-year window acknowledges that chronic health is not a series of isolated annual snapshots, but a continuous narrative that often gets interrupted by administrative “noise.” By looking back 24 months, we can identify persistent conditions like diabetes or heart disease that might have been missed in a single year’s reporting cycle due to a gap in visits, providing a more stable and accurate risk profile for the member. From a technical standpoint, health plans would first need to restructure their data warehouses to maintain longitudinal patient records that persist across enrollment cycles. They would then need to update their risk-adjustment algorithms to weigh historical data alongside current encounters, ensuring their reporting systems can cross-reference 2023 diagnoses with 2024 treatments to validate the ongoing nature of the illness.
Efforts to accelerate audits continue even as some regulatory rules face legal hurdles in court. What does a high-stakes audit look like for a private insurer, and what specific documentation proves that a member’s reported illness actually required the level of care claimed?
A high-stakes audit is an intensive, invasive process where the CMS or hired contractors demand the full clinical dossiers for thousands of randomly selected members to verify that the money paid out matches the care provided. It feels like a forensic investigation, where every single “ICD-10” code must be backed by a physician’s note, a diagnostic test result, or a clear treatment directive written at the time of service. To prove a member’s illness was real, insurers must produce “MEAT” documentation—evidence that the provider Monitored, Evaluated, Addressed, or Treated the condition during a face-to-face encounter. Without a specific lab result or a pharmacy record showing a prescribed medication for that illness, the government can claw back those funds, which can quickly add up to billions of dollars in recouped overpayments across a large plan.
Coding intensity in privatized plans remains significantly higher than in traditional government-managed Medicare. Why is there such a large gap in reported sickness between these two groups, and what strategies could reconcile these coding patterns to ensure a more equitable distribution of federal funds?
The gap exists because traditional Medicare generally lacks the profit-driven infrastructure to aggressively “mine” for every possible diagnosis, whereas private insurers have invested heavily in sophisticated coding software and risk-adjustment teams. This leads to a statistical anomaly where Medicare Advantage members appear much sicker on paper than their counterparts in the government-run program, even when their actual health outcomes are similar. To reconcile this, we need a standardized “coding intensity adjustment” that automatically scales back payments to private plans when their reported sickness levels deviate too far from the national average. By applying a universal discount factor to Medicare Advantage payments, we can neutralize the advantage of aggressive coding and ensure that taxpayer dollars are distributed based on actual clinical need rather than the efficiency of an insurer’s billing department.
What is your forecast for Medicare Advantage overpayment regulations?
I anticipate a significant tightening of the screws as bipartisan pressure mounts on the CMS to protect the solvency of the Medicare Trust Fund. We are likely to see the finalized exclusion of unlinked chart reviews within the next year, which will serve as a catalyst for insurers to shift their focus toward more integrated, encounter-based documentation. While legal challenges from private payers will undoubtedly slow the process, the sheer scale of the $76 billion discrepancy is becoming politically unsustainable, making accelerated audits the “new normal” for the industry. Ultimately, the future of the program will depend on a shift toward value-based metrics that reward actual health improvements in seniors rather than the sheer volume of diagnostic codes captured in a computer system.
